News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
334,219 Results
Type
Article (20097)
Company Profile (128)
Press Release (313994)
Multimedia
Podcasts (73)
Webinars (11)
Section
Business (105436)
Career Advice (880)
Deals (18538)
Drug Delivery (97)
Drug Development (50800)
Employer Resources (79)
FDA (7706)
Job Trends (7751)
News (185985)
Policy (17360)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (736)
Accelerated approval (3)
Adcomms (17)
Allergies (44)
Alliances (27868)
ALS (55)
Alzheimer's disease (643)
Antibody-drug conjugate (ADC) (96)
Approvals (7721)
Artificial intelligence (146)
Autoimmune disease (16)
Automation (6)
Bankruptcy (177)
Best Places to Work (5553)
BIOSECURE Act (13)
Biosimilars (98)
Biotechnology (57)
Bladder cancer (41)
Brain cancer (19)
Breast cancer (115)
Cancer (1118)
Cardiovascular disease (115)
Career advice (715)
Career pathing (21)
CAR-T (55)
Cell therapy (157)
Cervical cancer (5)
Clinical research (42762)
Collaboration (484)
Compensation (177)
Complete response letters (23)
COVID-19 (1101)
CRISPR (24)
C-suite (157)
Cystic fibrosis (58)
Data (1189)
Decentralized trials (2)
Denatured (18)
Depression (26)
Diabetes (144)
Diagnostics (1816)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (82)
Drug pricing (112)
Drug shortages (30)
Duchenne muscular dystrophy (61)
Earnings (39167)
Editorial (32)
Employer branding (10)
Employer resources (73)
Events (48782)
Executive appointments (467)
FDA (8323)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (321)
Gene editing (49)
Generative AI (18)
Gene therapy (148)
GLP-1 (603)
Government (1859)
Grass and pollen (3)
Guidances (23)
Healthcare (5904)
Huntington's disease (13)
IgA nephropathy (21)
Immunology and inflammation (88)
Indications (19)
Infectious disease (1183)
Inflammatory bowel disease (85)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (58)
Interviews (116)
IPO (7374)
IRA (45)
Job creations (2433)
Job search strategy (648)
Kidney cancer (7)
Labor market (24)
Layoffs (280)
Leadership (16)
Legal (4122)
Liver cancer (31)
Lung cancer (169)
Lymphoma (91)
Machine learning (3)
Management (30)
Manufacturing (216)
MASH (51)
Medical device (1965)
Medtech (1968)
Mergers & acquisitions (11433)
Metabolic disorders (509)
Multiple sclerosis (50)
NASH (20)
Neurodegenerative disease (50)
Neuropsychiatric disorders (23)
Neuroscience (972)
NextGen: Class of 2025 (2358)
Non-profit (908)
Northern California (1114)
Now hiring (22)
Obesity (320)
Opinion (191)
Ovarian cancer (35)
Pain (70)
Pancreatic cancer (39)
Parkinson's disease (87)
Partnered (11)
Patents (149)
Patient recruitment (49)
Peanut (16)
People (33530)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13393)
Phase II (18088)
Phase III (14528)
Pipeline (759)
Policy (127)
Postmarket research (1618)
Preclinical (4691)
Press Release (29)
Prostate cancer (64)
Psychedelics (16)
Radiopharmaceuticals (161)
Rare diseases (248)
Real estate (3175)
Recruiting (29)
Regulatory (12582)
Reports (22)
Research institute (820)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (62)
Series A (58)
Series B (34)
Service/supplier (7)
Sickle cell disease (36)
Southern California (1070)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2011)
State (2)
Stomach cancer (9)
Supply chain (55)
Tariffs (42)
The Weekly (53)
United States (10507)
Vaccines (280)
Venture capitalists (29)
Weight loss (244)
Women's health (14)
Worklife (8)
Date
Today (74)
Last 7 days (426)
Last 30 days (1305)
Last 365 days (16708)
2025 (5477)
2024 (17669)
2023 (19637)
2022 (25865)
2021 (26639)
2020 (24870)
2019 (20057)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (409)
Alabama (23)
Alaska (1)
Arizona (66)
Arkansas (8)
Asia (24942)
Australia (3228)
California (2623)
Canada (1137)
China (341)
Colorado (103)
Connecticut (102)
Delaware (77)
Europe (51542)
Florida (461)
Georgia (56)
Idaho (16)
Illinois (257)
India (20)
Indiana (176)
Iowa (3)
Japan (126)
Kansas (63)
Kentucky (17)
Louisiana (2)
Maine (4)
Maryland (378)
Massachusetts (2215)
Michigan (48)
Minnesota (139)
Mississippi (1)
Missouri (28)
Montana (10)
Nebraska (11)
Nevada (18)
New Hampshire (8)
New Jersey (1062)
New Mexico (21)
New York (777)
North Carolina (516)
North Dakota (2)
Northern California (1114)
Ohio (83)
Oklahoma (5)
Oregon (21)
Pennsylvania (634)
Puerto Rico (12)
Rhode Island (18)
South America (608)
South Carolina (3)
Southern California (1070)
Tennessee (38)
Texas (344)
Utah (57)
Virginia (88)
Washington D.C. (45)
Washington State (224)
Wisconsin (23)
334,219 Results for "fennec pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Fennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.
July 1, 2024
·
4 min read
Press Releases
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
February 7, 2025
·
10 min read
Press Releases
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
March 7, 2025
·
1 min read
Press Releases
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
March 10, 2025
·
17 min read
Press Releases
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - December 12, 2024
December 13, 2024
·
1 min read
Press Releases
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
November 14, 2024
·
1 min read
Business
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, reported its financial results for the first quarter ended March 31, 2024, and provided a business update.
May 14, 2024
·
14 min read
Bio NC
Fennec Announces Results of Annual Meeting - June 25, 2024
Fennec Pharmaceuticals Inc. announced that the nominees listed in the management proxy circular dated April 29, 2024 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024.
June 25, 2024
·
1 min read
Press Releases
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
December 20, 2024
·
10 min read
Business
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024.
May 7, 2024
·
1 min read
1 of 33,422
Next
